Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Abstract Kirsten Rat Sarcoma (KRAS) is a master oncogene involved in cellular proliferation
and survival and is the most commonly mutated oncogene in all cancers. Activating KRAS …

KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the
treatment of solid tumors. However, when compared to KRASG12C, selective inhibition of …

Cyclic peptides as a therapeutic modality are attracting a lot of attention due to their potential
for oral absorption and accessibility to intracellular tough targets. Here, starting with a drug …

Technological advances and breakthrough developments in the pharmaceutical field are
knocking at the door of the “undruggable” fortress with increasing insistence. Notably, the …

The development of potent, specific, and pharmacologically viable chemical probes and
therapeutics is a central focus of chemical biology and therapeutic development. However, a …

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are
identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC) …

Abstract Small GTPases including Ras, Rho, Rab, Arf, and Ran are omnipresent molecular
switches in regulating key cellular functions. Their dysregulation is a therapeutic target for …

Intracellular protein–protein interactions (PPIs) are challenging targets for traditional drug
modalities. Macrocyclic peptides (MPs) prove highly effective PPI inhibitors in vitro and can …